Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drug

The novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the contract is about $55.5 million.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news